51 related articles for article (PubMed ID: 38740647)
1. NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Young M; Tapia JC; Szabados B; Jovaisaite A; Jackson-Spence F; Nally E; Powles T
Clin Genitourin Cancer; 2024 Jun; 22(3):102072. PubMed ID: 38615487
[TBL] [Abstract][Full Text] [Related]
2. Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations.
Incorvaia L; Monteiro FSM; Massari F; Park SH; Roviello G; Fiala O; Myint ZW; Kucharz J; Molina-Cerrillo J; Santini D; Buttner T; Poprach A; Kopecky J; Zeppellini A; Pichler M; Buchler T; Pichler R; Facchini G; Fay AP; Soares A; Manneh R; Iezzi L; Kuronya Z; Russo A; Bourlon MT; Bhuva D; Ansari J; Kanesvaran R; Grande E; Buti S; Santoni M
Cancer Immunol Immunother; 2024 Jun; 73(8):142. PubMed ID: 38832989
[TBL] [Abstract][Full Text] [Related]
3. Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Chen J; Hu X; Zhao J; Yin X; Zheng L; Guo J; Chen J; Wang Y; Sheng X; Dong H; Liu X; Zhang X; Liang J; Liu H; Yao J; Liu J; Shen Y; Chen Z; He Z; Wang Y; Chen N; Nie L; Zhang M; Pan X; Chen Y; Liu H; Zhang Y; Tang Y; Zhu S; Zhao J; Dai J; Wang Z; Zeng Y; Wang Z; Huang H; Liu Z; Shen P; Zeng H; Sun G
Clin Cancer Res; 2024 Jun; 30(11):2571-2581. PubMed ID: 38512114
[TBL] [Abstract][Full Text] [Related]
4. MMP1, IL-1β, sTNFR-1, and IL-6 are prognostic factors for patients with unresectable or metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Nagasaka H; Kishida T; Kouro T; Igarashi Y; Takebe S; Yamamoto S; Kondo T; Koizumi M; Terao H; Suzuki T; Nakaigawa N; Himuro H; Wei F; Sasada T
Int J Clin Oncol; 2024 Jun; 29(6):832-839. PubMed ID: 38580797
[TBL] [Abstract][Full Text] [Related]
5. Tumor infiltrating B lymphocytes (TIBs) associate with poor clinical outcomes, unfavorable therapeutic benefit and immunosuppressive context in metastatic clear cell renal cell carcinoma (mccRCC) patients treated with anti-PD-1 antibody plus Axitinib.
Lin Z; Xiao S; Qi Y; Guo J; Lu L
J Cancer Res Clin Oncol; 2024 May; 150(5):262. PubMed ID: 38762825
[TBL] [Abstract][Full Text] [Related]
6. Soluble Immune Checkpoint Molecules as Predictors of Efficacy in Immuno-Oncology Combination Therapy in Advanced Renal Cell Carcinoma.
Ueda K; Uemura K; Ito N; Sakai Y; Ohnishi S; Suekane H; Kurose H; Hiroshige T; Chikui K; Nishihara K; Nakiri M; Suekane S; Ogasawara S; Yano H; Igawa T
Curr Oncol; 2024 Mar; 31(4):1701-1712. PubMed ID: 38668032
[TBL] [Abstract][Full Text] [Related]
7. Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of "palateau".
Rebuzzi SE; Fornarini G; Signori A; Rescigno P; Banna GL; Buti S
Hum Vaccin Immunother; 2024 Dec; 20(1):2351669. PubMed ID: 38757563
[TBL] [Abstract][Full Text] [Related]
8. Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes.
Saliby RM; Labaki C; Jammihal TR; Xie W; Sun M; Shah V; Saad E; Kane MH; Kashima S; Sadak K; El Zarif T; Poduval D; Motzer RJ; Powles T; Rini BI; Albiges L; Pal SK; McGregor BA; McKay RR; Signoretti S; Van Allen EM; Shukla SA; Choueiri TK; Braun DA
Cancer Cell; 2024 May; 42(5):732-735. PubMed ID: 38579722
[TBL] [Abstract][Full Text] [Related]
9. Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances.
Salgia NJ; Zengin ZB; Pal SK; Dizman N
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438642. PubMed ID: 38776514
[TBL] [Abstract][Full Text] [Related]
10. Neopterin as a potential prognostic and predictive biomarker in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Studentova H; Hola K; Melichar B; Spisarova M
Expert Rev Anticancer Ther; 2024 Jun; 24(6):339-345. PubMed ID: 38596831
[TBL] [Abstract][Full Text] [Related]
11. Tumor microenvironment and clinical efficacy of first line immunotherapy-based combinations in metastatic renal cell carcinoma.
Sammarco E; Rossetti M; Salfi A; Bonato A; Viacava P; Masi G; Galli L; Faviana P
Med Oncol; 2024 May; 41(6):150. PubMed ID: 38740647
[TBL] [Abstract][Full Text] [Related]
12. Update on Biomarkers in Renal Cell Carcinoma.
Saliby RM; Saad E; Kashima S; Schoenfeld DA; Braun DA
Am Soc Clin Oncol Educ Book; 2024 Jan; 44(2):e430734. PubMed ID: 38207251
[TBL] [Abstract][Full Text] [Related]
13. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles.
Govindarajan A; Salgia NJ; Li H; Castro DV; Mirzapoiazova T; Armstrong B; Zhao D; Mercier BD; Dizman N; Chawla N; Zengin Z; Meza L; Tripathi N; Sayegh N; Chehrazi-Raffle A; Tripathi A; Pal SK
Front Immunol; 2023; 14():1182581. PubMed ID: 37638025
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.
Plimack ER; Powles T; Stus V; Gafanov R; Nosov D; Waddell T; Alekseev B; Pouliot F; Melichar B; Soulières D; Borchiellini D; McDermott RS; Vynnychenko I; Chang YH; Tamada S; Atkins MB; Li C; Perini R; Molife LR; Bedke J; Rini BI
Eur Urol; 2023 Nov; 84(5):449-454. PubMed ID: 37500340
[TBL] [Abstract][Full Text] [Related]
15. Macrophages in immunoregulation and therapeutics.
Chen S; Saeed AFUH; Liu Q; Jiang Q; Xu H; Xiao GG; Rao L; Duo Y
Signal Transduct Target Ther; 2023 May; 8(1):207. PubMed ID: 37211559
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study.
Rebuzzi SE; Brunelli M; Galuppini F; Vellone VG; Signori A; Catalano F; Damassi A; Gaggero G; Rescigno P; Maruzzo M; Merler S; Vignani F; Cavo A; Basso U; Milella M; Panepinto O; Mencoboni M; Sbaraglia M; Dei Tos AP; Murianni V; Cremante M; Llaja Obispo MA; Maffezzoli M; Banna GL; Buti S; Fornarini G
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190322
[TBL] [Abstract][Full Text] [Related]
17. The Tumor Immune Microenvironment in Clear Cell Renal Cell Carcinoma.
Monjaras-Avila CU; Lorenzo-Leal AC; Luque-Badillo AC; D'Costa N; Chavez-Muñoz C; Bach H
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175653
[TBL] [Abstract][Full Text] [Related]
18. Erratum: Nivolumab Plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC): 3-Year Follow-Up From the Phase 3 CheckMate 9 ER Trial.
J Clin Oncol; 2023 Jul; 41(21):3767. PubMed ID: 37159880
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
